Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine

RR Amara, F Villinger, JD Altman, SL Lydy, SP O'Neil… - Science, 2001 - science.org
RR Amara, F Villinger, JD Altman, SL Lydy, SP O'Neil, SI Staprans, DC Montefiori, Y Xu…
Science, 2001science.org
Heterologous prime/boost regimens have the potential for raising high levels of immune
responses. Here we report that DNA priming followed by a recombinant modified vaccinia
Ankara (rMVA) booster controlled a highly pathogenic immunodeficiency virus challenge in
a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed
multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a
single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered …
Heterologous prime/boost regimens have the potential for raising high levels of immune responses. Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered 7 months after the booster. These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic.
AAAS